At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 20 enrolled
Drug / intervention
cabergolinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Phase II Trial of Cabergoline in the Treatment of Metastatic Breast Cancer
In Brief
A Early Phase 1 clinical trial evaluating cabergoline for Recurrent Breast Cancer and Stage IV Breast Cancer. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Prolactin is a hormone produced in the pituitary gland. Previous studies have revealed that elevated levels of the hormone prolactin might be associated with an increased risk of breast cancer. Cabergoline has been shown to lower prolactin levels in the blood. The purpose of this study is to evaluate the effectiveness of cabergoline in treating metastatic breast cancer disease in those who test positive for the prolactin receptor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Breast Cancer, Stage IV Breast Cancer
CountriesUnited States
CollaboratorsLynn Sage Foundation
Timeline
Early Ph 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartFeb 2013
Primary CompletionDec 2015
Study CompletionOct 2017
TodayJul 2026
First PostedNov 21, 2012
Enrollment StartFeb 11, 2013
Primary CompletionDec 15, 2015
Study CompletionOct 27, 2017
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.6 years ago
Interventions
cabergolinedrug
Given orally